Bariatric Endoscopy in the GLP-1 Era : Frontline Gastroenterol | June 2026

Introduction:

Introduction: Obesity affects more than one billion individuals globally and is a major driver of type 2 diabetes, cardiovascular disease, metabolic dysfunction–associated steatotic liver disease (MASLD), and multiple obesity-related cancers. While incretin-based therapies such as GLP-1 and dual agonists have transformed medical obesity management, concerns remain regarding long-term adherence, treatment costs, access, and weight regain following discontinuation. These limitations have renewed interest in metabolic and bariatric endoscopy (MBE) as a minimally invasive treatment modality positioned between pharmacotherapy and bariatric surgery.

Problem Statement:

Problem Statement: The rapid success of highly effective anti-obesity medications has raised questions about the future role of endoscopic bariatric therapies. Determining how endoscopic interventions can complement pharmacotherapy, provide durable weight loss, and address metabolic disease remains a critical challenge for obesity care pathways.

Summary:

Summary: This review examines the evolving role of bariatric metabolic endoscopy and its future position within modern obesity management.

Current endoscopic therapies target multiple components of the gut–metabolic axis and can be broadly classified into gastric-directed, small bowel-directed, and pancreatic-directed interventions.

Among gastric therapies, endoscopic sleeve gastroplasty (ESG) remains the most established procedure. By reducing gastric volume through endoscopic suturing, ESG promotes early satiety, delays gastric emptying, and induces clinically meaningful weight loss with a favorable safety profile. Long-term studies continue to demonstrate sustained metabolic benefits, particularly when combined with multidisciplinary lifestyle interventions.

Intragastric balloons remain an option for selected patients requiring temporary weight reduction, although durability and tolerability limitations have restricted their long-term role. Newer generation devices and swallowable balloon technologies aim to improve patient acceptance and safety.

Small bowel-directed therapies focus on modifying nutrient exposure and enteroendocrine signaling. Techniques such as duodenal mucosal resurfacing and other endoscopic duodenal interventions seek to improve insulin sensitivity and glycemic control by altering proximal intestinal nutrient sensing. These approaches are particularly attractive for patients with obesity-associated type 2 diabetes.

Emerging pancreatic-directed endoscopic therapies are based on the concept of modifying neurohormonal pathways involved in appetite regulation, glucose homeostasis, and energy metabolism. Although still largely investigational, these technologies may represent future therapeutic targets within the gut–brain–pancreas axis.

A major theme of the review is the integration of endoscopic therapies with incretin-based pharmacotherapy rather than viewing them as competing strategies. Combination approaches may offer synergistic benefits by enhancing weight loss magnitude, improving durability, reducing medication requirements, and minimizing weight regain after drug discontinuation.

The future of obesity treatment is increasingly moving toward personalized therapy selection. Patients with moderate obesity, inadequate response to pharmacotherapy, medication intolerance, or reluctance to undergo surgery may represent ideal candidates for bariatric endoscopy.

The review also highlights the expanding relevance of metabolic endoscopy beyond weight reduction alone. Improvements in diabetes control, MASLD, cardiovascular risk factors, and obesity-related quality of life are becoming important therapeutic targets and may ultimately drive patient selection.

As obesity is increasingly recognized as a chronic relapsing disease, bariatric endoscopy is expected to become an integral component of comprehensive obesity care pathways, functioning alongside lifestyle modification, pharmacotherapy, and surgery within a multidisciplinary precision medicine framework.

Overall, bariatric metabolic endoscopy is evolving from a niche intervention into a key pillar of obesity management, with future success likely to depend on strategic integration with incretin therapies, individualized patient selection, and continued innovation across the gut–metabolic axis.